Table 2:

Risk of acute pancreatitis associated with use of postmenopausal HRT (1997–2010)

HRT	No. of women	No. of cases/person-years	Age-adjusted RR (95% CI)	Multivariable RR (95% CI)*
Never users	14 721	98/178 430	1.00 (ref)	1.00 (ref)
Ever users	16 773	139/211 026	1.41 (1.08–1.83)	1.57 (1.20–2.05)
Current use
No	3 660	36/45 144	1.49 (1.01–2.18)	1.58 (1.07–2.32)
Yes	13 113	103/165 882	1.38 (1.04–1.83)	1.56 (1.17–2.09)
Duration of use, yr†
< 5	5 937	46/75 238	1.45 (1.01–2.07)	1.59 (1.10–2.29)
5–10	3 463	32/43 797	1.53 (1.02–2.29)	1.73 (1.14–2.61)
>10	1 372	17/16 648	1.62 (0.97–2.71)	1.87 (1.11–3.17)
Type of therapy used‡
Local	4 307	38/53 099	1.21 (0.83–1.76)	1.37 (0.94–2.00)
Systemic	9 115	75/116 419	1.66 (1.21–2.28)	1.92 (1.38–2.66)

Note: CI = confidence interval, HRT = hormone replacement therapy, ref = reference group, RR = relative risk.

^*Derived from a Cox proportional hazards model with age as time scale and with adjustment for age at menopause (< 51 or ≥ 51 yr), education (less than high school, high school or university), smoking status (never, past [as < 10 or ≥ 10 pack-years] or current [as < 20 or ≥ 20 pack-years]), body mass index (< 25, 25–29 or ≥ 30), alcohol intake (quartiles [g/d]) and vegetable consumption (quartiles [servings/d]).

^†Sum of categories is less than the total of 16 773 women who were ever users because data on duration of use were missing for 6001 women (including 44 cases).

^‡Categories refer to women who were exposed exclusively to either systemic therapy or local therapy. In addition, 3351 women (including 26 cases) reported having ever used both types of therapy.